ML
$21.47
+0.37
(+1.75%)
As of Oct 22, 2026, 8:08 PM EDT · cached
Price history
Mineralys Therapeutics Inc (MLYS) is trading up at $21.47 (+1.75%), as of the latest quote. It is a Russell 2000 constituent in the Health Care sector.
IPO: February 10, 2023 · $16.00 offering · NASDAQ · View IPO details →
Mineralys Therapeutics Inc net income history (FY2022–FY2025)
Net income
| FY2022Dec 2022 | FY2023Dec 2023 | FY2024Dec 2024 | FY2025Dec 2025 | |
|---|---|---|---|---|
| Income statement | ||||
| Operating income | −$31.5M | −$84.7M | −$192.4M | −$170.6M |
| Net income | −$29.8M | −$71.9M | −$177.8M | −$154.7M |
| EPS (diluted) | −$5.77 | −$1.99 | −$3.66 | −$2.29 |
| Balance sheet | ||||
| Cash and equivalents | $87.7M | $49.3M | $114.1M | $172.9M |
| Total assets | $114.4M | $251.6M | $205.9M | $661.8M |
| Total liabilities | $166.7M | $10.5M | $14.6M | $15.1M |
| Shareholders' equity | −$52.3M | $241.2M | $191.3M | $646.7M |
| Cash flow | ||||
| Operating cash flow | −$29.2M | −$81.2M | −$166.3M | −$142.4M |
| Capital expenditure | — | $0 | $96.0K | $15.0K |
| Free cash flow | — | −$81.2M | −$166.4M | −$142.4M |
Net income
| Q3 FY24Sep 2024 | Q4 FY24†Dec 2024 | Q1 FY25Mar 2025 | Q2 FY25Jun 2025 | Q3 FY25Sep 2025 | Q4 FY25†Dec 2025 | Q1 FY26Mar 2026 | Q2 FY26Jun 2026 | |
|---|---|---|---|---|---|---|---|---|
| Income statement | ||||||||
| Operating income | −$60.1M | −$51.8M | −$44.4M | −$46.7M | −$41.1M | −$38.3M | −$45.3M | −$246.0M |
| Net income | −$56.3M | −$48.9M | −$42.2M | −$43.3M | −$36.9M | −$32.2M | −$39.3M | −$241.1M |
| EPS (diluted) | −$1.13 | −$1.00 | −$0.79 | −$0.66 | −$0.52 | −$0.32 | −$0.47 | −$2.85 |
| Balance sheet | ||||||||
| Cash and equivalents | $97.3M | $114.1M | $165.0M | $101.8M | $217.6M | $172.9M | $112.8M | $138.3M |
| Total assets | $268.3M | $205.9M | $354.9M | $335.7M | $599.9M | $661.8M | $652.9M | $667.9M |
| Total liabilities | $31.3M | $14.6M | $13.4M | $22.2M | $23.5M | $15.1M | $14.7M | $116.9M |
| Long-term debt | — | — | — | — | — | — | — | $100.0K |
| Shareholders' equity | $236.9M | $191.3M | $341.6M | $313.6M | $576.4M | $646.7M | $638.1M | $550.9M |
| Cash flow | ||||||||
| Operating cash flow | −$50.2M | −$66.8M | −$45.5M | −$30.2M | −$28.9M | −$37.9M | −$39.5M | −$32.6M |
| Capital expenditure | $37.0K | $0 | $0 | $0 | $0 | $15.0K | — | — |
| Free cash flow | −$50.2M | −$66.8M | −$45.5M | −$30.2M | −$28.9M | −$37.9M | — | — |
From Mineralys Therapeutics Inc's 10-K and 10-Q filings with the SEC; its fiscal year ends in December. Each period shows the latest figure the company has reported for it, including restatements. † Quarter derived from the company's year-to-date or full-year totals. Filings on SEC EDGAR →
About Mineralys Therapeutics Inc
- Headquarters
- Radnor, Pennsylvania From SEC filings, Oct 2026
Recent News (1)
More Health Care stocks
- ILMN Illumina
- A Agilent Technologies
- ABBV AbbVie
- ABT Abbott Laboratories
- ALGN Align Technology
- ALNY Alnylam Pharmaceuticals
- AMGN Amgen
- BAX Baxter International